Table 4.
In vitro drug susceptibility in different parasite phenotype.
| Different parasite phenotype | PC1/2 > 5 h | Culture adaptation | RSA (0–3 h) (mean) | IC50 nMol/L pyrimethamine (mean) | IC50 nMol/L sulfadoxine (mean) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sensitive < 1% | RS ≥ 1% | S < 100 nM | IR 100–2000 nM | R > 2000n M | S < 640 nM | IR 640–3000 nM | R > 3000 nM | |||
| Rapid clearing parasite (PCT ≤ 36 h) | 0/47 | 45/47 | 0.19% (95% CI 0.14–0.25) 45/45 | – | 72.43 (95% CI 55.8–88) 12/45 | 1161.25 (95% CI 523.7–1794.2) 17/45 | 2512.82 (95% CI 2050.2–29.72) 16/45 | 372.24 (95% CI 236.3–510.1) 21/45 | 2271.41 (95% CI 1685.4–2860) 14/45 | 3570.27 (95% CI 3149.2–3987.7) 10/45 |
| Parasite clearance normal (PCT > 36 h ≤ 48 h | 0/72 | 62/72 | 0.23% (95% CI 0.15–0.32) 62/62 | – | 77.21 (95% CI 64.5–91) 8/62 | 1330.62 (95% CI 767.3–1891.4) 25/62 | 4696.70 (95% CI 2675.1–6720) 29/62 | 426.29 (95% CI 291.4–564.3) 12/62 | 2349.60 (95% CI;1821.5–2875.8) 28/62 | 5642.51 (95% CI 4276.2–7012.7) 22/62 |
| Delayed clearing parasite) (PCT > 48- ≤ 72 h) | 8/52 | 41/52 | 0.33% (95% CI 0.22–0.46 37/41 | 1.92% (95% CI 1.83–2.02) 4/41 | 88.9 (95% CI 88–90) 2/41 | 1741.35 (95% CI 1562.8–1920.5) 12/41 | 7442.39 (95% CI 5486–9400.2) 27/41 | 412.54 (95% CI 408.1–417.2) 3/41 | 2718.50 (95% CI 2635.5–2804.1) 6/41 | 8156.17 (95% CI 6480.7–9832.3) 32/41 |
|
Very slow clearing parasite PCT > 72 h |
9/9 | 8/9 |
0.94% 1/8 |
2.76% (95% CI 2.43–3.09) 7/8 | – |
1887.45 1/8 |
8004.17 (95% CI 6780.3–9235) 7/8 | – | – |
8397 (95% CI 7117.2–9680.6) 8/8 |
| 3D7 | 0.17% (95% CI 0.14–0.19 | – | 68.42 ± 2·1 | – | – | – | – | 4320.50 ± 32.65 | ||
Individual ex-vivo ring stage survivability of parasite isolates was represented as RSA. Here S, IR, R and RS stand for Sensitive, Intermittent resistant, Resistant, and Reduced susceptibility, respectively. Parasite clearance time was denoted as PCT and Parasite clearance half-life was denoted as PC1/2.